Minerva Neurosciences (NASDAQ:NERV – Get Free Report) and KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.
Analyst Recommendations
This is a summary of recent recommendations for Minerva Neurosciences and KalVista Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Minerva Neurosciences | 1 | 1 | 1 | 0 | 2.00 |
| KalVista Pharmaceuticals | 1 | 5 | 3 | 0 | 2.22 |
Minerva Neurosciences currently has a consensus price target of $10.50, indicating a potential upside of 98.11%. KalVista Pharmaceuticals has a consensus price target of $30.60, indicating a potential upside of 14.31%. Given Minerva Neurosciences’ higher possible upside, research analysts plainly believe Minerva Neurosciences is more favorable than KalVista Pharmaceuticals.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Minerva Neurosciences | N/A | N/A | -$293.42 million | ($29.16) | -0.18 |
| KalVista Pharmaceuticals | $49.08 million | 29.04 | -$109.52 million | ($3.46) | -7.74 |
KalVista Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Minerva Neurosciences and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Minerva Neurosciences | N/A | N/A | -32.63% |
| KalVista Pharmaceuticals | N/A | -341.44% | -111.94% |
Volatility and Risk
Minerva Neurosciences has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500.
Insider and Institutional Ownership
34.6% of Minerva Neurosciences shares are owned by institutional investors. 10.4% of Minerva Neurosciences shares are owned by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Minerva Neurosciences beats KalVista Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
